CompletedInterventionalPhase 4Updated Jan 28, 2014
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension | NCT01830140 | Trialant
CompletedInterventionalPhase 3Updated May 6, 2015
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
ClinicalTrials.gov ID
NCT01830140
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
466Actual
Last Update Posted
May 6, 2015Estimated
Start Date
Jul 2013
Primary Completion Date
May 2014Actual
Completion Date
May 2014Actual
Brief Summary
This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).
Glaucoma
Ocular Hypertension
Bimatoprost 0.01%
Bimatoprost 0.03%
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of glaucoma or ocular hypertension
Exclusion Criteria:
Active ocular disease other than glaucoma or ocular hypertension
Require chronic use of ocular medications other than the study medication during the study (intermittent use of artificial tear solution will be permitted)